Moreover, we also demonstrated for the first time that a selective A2AR antagonist (KW6002) administered orally has therapeutic interest against transient retinal ischemic damage, suggesting that A2AR antagonist can be further studied to manage retinal ischemic diseases or neurodegenerative diseases. The gene discussed is ADORA2A; the disease is neurodegenerative disease.